Respiratory Distress Syndrome clinical trials at UC Irvine

3 in progress, 2 open to eligible people

Showing trials for

  • Add-on Reparixin in Adult Patients With ARDS

    open to eligible people ages 18 years and up

    Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.

    Orange, California and other locations

  • Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

    open to eligible people ages 18 years and up

    BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.

    Irvine, California and other locations

  • Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

    Sorry, in progress, not accepting new patients

    This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.

    Irvine, California and other locations

Last updated: